Solid Biosciences Inc. (SLDB) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 167.40M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 21.20M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -212.15M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $167.40M | (m) | $21.20M | $-212.15M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $155.55M | (m) | $18.73M | $-196.46M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $140.32M | (m) | $16.91M | $-179.21M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $132.96M | (m) | $14.23M | $-169.70M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $121.43M | (m) | $13.30M | $-156.82M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $108.47M | (m) | $12.25M | $-142.92M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $96.43M | (m) | $10.52M | $-129.73M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $81.11M | (m) | $8.64M | $-112.10M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $70.49M | (m) | $7.27M | $-100.03M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $70.81M | (m) | $7.12M | $-99.08M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $76.56M | (m) | $7.63M | $-104.25M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $82.40M | (m) | $7.27M | $-116.55M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $79.70M | (m) | $7.17M | $-114.57M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $83.11M | (m) | $7.04M | $-113.11M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $78.42M | $8.09M | $7.54M | $-106.45M | (m) | 968.87% | 93.12% | (m) | (m) |
| 2022-09-30 | $71.72M | (m) | $9.37M | $-90.54M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $72.14M | (m) | $11.26M | $-87.44M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $64.48M | (m) | $13.08M | $-80.74M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $58.74M | $13.62M | $13.37M | $-72.25M | (m) | 431.27% | 98.19% | (m) | (m) |
| 2021-09-30 | $59.87M | (m) | $12.48M | $-74.95M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $61.49M | (m) | $11.82M | $-78.14M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $59.42M | (m) | $11.43M | $-78.43M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $64.88M | $0.00 | $11.63M | $-88.41M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $76.22M | $0.00 | $12.52M | $-99.39M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $82.97M | $0.00 | $13.14M | $-107.88M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $91.13M | $0.00 | $13.81M | $-115.88M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $94.74M | $0.00 | $14.21M | $-119.32M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $85.43M | $0.00 | $12.83M | $-109.37M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $77.32M | $0.00 | $11.24M | $-98.81M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $69.31M | $0.00 | $8.64M | $-90.02M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $57.97M | $0.00 | $5.96M | $-75.69M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $39.91M | $0.00 | $5.33M | $-54.86M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $20.12M | $0.00 | $1.47M | $-25.58M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |